Sign in
Not yet taking people in South KoreaPhase 3

Eloralintide and tirzepatide combined for weight loss in adults with obesity

Tests eloralintide with tirzepatide for weight loss in adults with obesity.

Key facts

Who runs it
Eli Lilly and Company
Where
Ansan-si, Busan, Guri-si, Gwangju, Gyeongsan-si, Junggu, Namdong-gu, Seogu, Seongnam, Seongnam-si, and Seoul, South KoreaSee the 13 sitesAlso in 8 other countries, 142 sites
Registry title
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
Status
Not yet recruiting
Phase
Phase 3
People taking part
2,115 people, planned
Starts
Dec 2026
Expected to end
Nov 2029
Type of study
Interventional, 8 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • eloralintide and tirzepatide
  • Eloralintide
  • Tirzepatide
  • Placebo
Record updated
3 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obesity who do not have diabetes. It compares a combined drug (eloralintide and tirzepatide) with tirzepatide alone, eloralintide alone and placebo for weight loss.

Age
18 years or older
Sex
Men and women can join
Disease stage
Obesity with a BMI of 35 kg/m2 or more at screening. No diabetes of any type.
Earlier treatment
At least 1 self-reported unsuccessful diet attempt to lose weight. Stable body weight (less than 5% change) for 90 days before screening. No glucose-lowering medication and no weight-loss medication or remedies in the 90 days before screening.

Main reasons for not taking part

  • Type 1 diabetes, type 2 diabetes or any other type of diabetes
  • Prior or planned surgery for obesity, with limited exceptions if done more than 1 year before screening
  • Prior or planned endoscopic procedure or device-based therapy for obesity or type 2 diabetes, with an exception if the device was removed more than 6 months before screening
  • Heart attack, stroke, coronary artery revascularization, unstable angina or hospital stay for heart failure in the 90 days before screening
  • New York Heart Association Class IV congestive heart failure

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Have a stable self-reported body weight (<5% body weight change) for 90 days prior to screening
  • Have a BMI of ≥35 kg/m2 at screening
  • Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight

Who cannot take part

  • Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
  • Have a prior or planned endoscopic procedure and/or device-based therapy for obesity and/or type 2 diabetes (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
  • Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure
  • Have taken medications or alternative remedies intended for weight loss within 90 days of screening
  • Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
  • Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
  • Have taken any glucose-lowering medication within 90 days of screening

Where in South Korea

Also in 8 other countries, 142 sites

  • Korea University Ansan HospitalAnsan-si, South KoreaContact: NANHEE KIM (principal investigator)Not yet recruiting
  • Pusan National University Yangsan HospitalBusan, South KoreaContact: Sang Yeoup Lee (principal investigator)Not yet recruiting
  • Hanyang University Guri HospitalGuri-si, South KoreaContact: Sangmo Hong (principal investigator)Not yet recruiting
  • Chosun University HospitalGwangju, South KoreaContact: Sang Yong Kim (principal investigator)Not yet recruiting
  • Yeungnam Univeristy Medical CenterGyeongsan-si, South KoreaContact: KYUCHANG WON (principal investigator)Not yet recruiting
  • Kyungpook National University HospitalJunggu, South KoreaContact: Hae-Jin Ko (principal investigator)Not yet recruiting
  • Gachon University Gil Medical CenterNamdong-gu, South KoreaContact: Kyoung-Kon Kim (principal investigator)Not yet recruiting
  • Konyang University HospitalSeogu, South KoreaContact: Jee Hyun Kang (principal investigator)Not yet recruiting
  • Seoul National University Bundang HospitalSeongnam, South KoreaContact: Kiheon Lee (principal investigator)Not yet recruiting
  • CHA Bundang Medical Center, CHA UniversitySeongnam-si, South KoreaContact: Young-Sang Kim (principal investigator)Not yet recruiting
  • Nowon Eulji Medical Center, Eulji UniversitySeoul, South KoreaContact: kyungwan Min (principal investigator)Not yet recruiting
  • Seoul National University HospitalSeoul, South KoreaContact: BeLong Cho (principal investigator)Not yet recruiting
  • Severance Hospital, Yonsei University Health SystemSeoul, South KoreaContact: Byung Wan Lee (principal investigator)Not yet recruiting

About the trial

What the trial wants to find out

The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with obesity.

Read full original descriptionShow less

Participation in the study will last about 2 years.

The 8 groups in the trial

  • EloraTZP Dose 1Treatment being tested

    Participants will receive EloraTZP subcutaneously (SC)

    Treatment: eloralintide and tirzepatide

  • EloraTZP Dose 2Treatment being tested

    Participants will receive EloraTZP SC

    Treatment: eloralintide and tirzepatide

  • EloraTZP Dose 3Treatment being tested

    Participants will receive EloraTZP SC

    Treatment: eloralintide and tirzepatide

  • EloraTZP Dose 4Treatment being tested

    Participants will receive EloraTZP SC

    Treatment: eloralintide and tirzepatide

  • EloraTZP Dose 5Treatment being tested

    Participants will receive EloraTZP SC

    Treatment: eloralintide and tirzepatide

  • TirzepatideTreatment being tested

    Participants will receive tirzepatide SC

  • EloralintideTreatment being tested

    Participants will receive eloralintide SC

  • PlaceboPlacebo, for comparison

    Participants will receive placebo SC

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 3 Study to Investigate the Efficacy and Safety of LY900043 in Adult Participants With Obesity Without Type 2 Diabetes
Plain-language title
Eloralintide and tirzepatide combined for weight loss in adults with obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
3 November 2026